What was the rationale behind using RANO-HGG criteria instead of RAPNO criteria for the primary endpoint in the FIREFLY-1 trial for pLGG?
How will you implement response assessments in patients starting tovorafenib given potential for pseudoprogression vs true progression?
Community PollStarted
How will you implement response assessments in patients starting tovorafenib for pLGG?
1 physician has voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto Faculty of Medicine
Answered on
I think this was a mistake, but I understand that this was requested by the FDA. We all know that MEK and BRAF inhibitors change the pattern of enhancement within days/weeks after the beginning of the treatment. As RANO-HGG is essentially based on the assessment of enhancing measurable and nonmeasur...
Join for free or sign in to see the full answer
Mednet Member
Pediatric Hematology/Oncology · The Brain Tumor Institute
Answered on
The primary endpoint for the FIREFLY-1 trial was the overall response rate using RANO-HGG because, at the time the protocol was designed, this was the only clinically validated response criteria for brain tumors. However, more recently the RAPNO-LGG criteria were published which focuses on T2 weight...
Join for free or sign in to see the full answer